Routine

Urinary incontinence in adults (stress, urgency/OAB, mixed, overflow, functional)

Genitourinary / Geriatric · Geriatric & General
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Involuntary leakage of urine; common, under-reported and often treatable. Classify by type to guide management: stress (leak on cough/exertion — sphincter/pelvic floor weakness), urgency/overactive bladder (sudden compelling urge, detrusor overactivity), mixed, overflow (chronic retention — BPH, neurogenic, drugs), and functional (mobility/cognition prevent reaching toilet). Always first exclude and treat reversible causes (the 'DIAPPERS': Delirium, Infection (symptomatic UTI), Atrophic vaginitis, Pharmaceuticals, Psychological, Excess urine output, Restricted mobility, Stool impaction).

Red flags

  • Visible haematuria, or microscopic haematuria in adults >=45 with risk factors — 2-week-wait for bladder cancer
  • Painful bladder, recurrent UTIs, suspected fistula or malignant mass
  • New neurological signs / suspected cauda equina (saddle anaesthesia, bilateral leg symptoms, acute retention with overflow) — emergency
  • Palpable bladder / high post-void residual (obstruction, risk of obstructive AKI)
  • Pelvic organ prolapse beyond introitus

Assessment

Differential diagnosis

  • Stress urinary incontinence (pelvic floor/sphincter weakness, post-prostatectomy)
  • Urgency incontinence / overactive bladder (detrusor overactivity)
  • Mixed incontinence
  • Overflow incontinence / chronic retention (BPH, neurogenic bladder, anticholinergic/opioid drugs, faecal impaction)
  • Functional incontinence (immobility, dementia, environment)
  • Fistula (vesicovaginal — obstetric, post-surgical, post-radiation; consider in India post-obstructed labour)
  • Reversible: symptomatic UTI, atrophic vaginitis, diuretics/hyperglycaemia/hypercalcaemia, constipation, delirium

Investigations

  • Bladder diary (frequency/volume chart) over 3 days
  • Urinalysis — treat only if symptomatic UTI; do NOT treat asymptomatic bacteriuria
  • Post-void residual (bladder scan) — exclude chronic retention/overflow (e.g. >150-200 mL abnormal) [verify local threshold]
  • U&E, glucose, calcium (polyuria causes)
  • Examination: abdominal (palpable bladder), pelvic (prolapse, atrophy), cough stress test, DRE (prostate, faecal impaction, tone), neurological if indicated
  • Specialist: urodynamics before surgery or when diagnosis unclear

Management

  • Identify and reverse DIAPPERS causes first (treat symptomatic UTI, relieve constipation, review drugs, treat atrophy)
  • Classify incontinence type clinically
  • Lifestyle first-line: weight loss if BMI high, reduce caffeine/alcohol, modify fluid intake (not excessive restriction), smoking cessation, timed/prompted voiding, treat constipation
  • Stress UI: supervised pelvic floor muscle training >=3 months (>=8 contractions x3/day); then consider surgery (colposuspension, autologous sling) or duloxetine if surgery declined
  • Urgency UI/OAB: bladder retraining >=6 weeks; then antimuscarinic or mirabegron; consider botulinum toxin A, percutaneous tibial nerve stimulation or sacral neuromodulation if refractory
  • Overflow/retention: relieve retention (catheter), treat cause (alpha-blocker +/- 5-alpha-reductase inhibitor for BPH, review anticholinergics), teach intermittent self-catheterisation if neurogenic
  • Functional: optimise mobility, toileting aids, commode, clothing, containment products as adjunct not substitute
  • Refer to continence service / urogynaecology / urology if red flags, refractory, or surgery considered

Drugs & doses

Antimuscarinic for OAB: oxybutynin MR 5-10 mg PO once daily, or solifenacin 5-10 mg PO once daily, or tolterodine MR 4 mg PO once daily, or trospium 20 mg PO twice daily (prefer once-daily/trospium in older adults; AVOID immediate-release oxybutynin in frail elderly — anticholinergic burden/cognition) [verify local dose]
Mirabegron 25-50 mg PO once daily (beta-3 agonist; preferred in cognitive impairment/high anticholinergic burden; caution/avoid in uncontrolled hypertension) [verify local dose]
Duloxetine 40 mg PO twice daily for stress UI when surgery not wanted (second-line; nausea common) [verify local dose]
Topical vaginal oestrogen (e.g. estriol cream or estradiol pessary) for urogenital atrophy with OAB/UI in postmenopausal women [verify local dose]
For overflow due to BPH: tamsulosin 400 micrograms PO once daily +/- finasteride 5 mg PO once daily [verify local dose]
Botulinum toxin A 100 units intradetrusor injection for refractory OAB (specialist; counsel re self-catheterisation risk) [verify local dose]

Disposition

Outpatient; refer to continence service/urogynaecology/urology for refractory cases, surgery, suspected malignancy or neurological cause. Urgent referral for red flags.

Complications & pitfalls

  • Obstructive uropathy / AKI from unrecognised chronic retention
  • Recurrent UTI, skin breakdown / incontinence-associated dermatitis, pressure ulcers
  • Falls (nocturia, rushing to toilet), social isolation, depression, carer strain, institutionalisation
  • Anticholinergic cognitive decline from OAB drugs

Exam pearls

  • Guideline: NICE NG123 (urinary incontinence and pelvic organ prolapse in women); OAB management per NICE/EAU.
  • Always exclude chronic retention with overflow before starting an antimuscarinic — it will worsen retention.
  • Prefer mirabegron or once-daily/trospium antimuscarinics in older/cognitively impaired patients; immediate-release oxybutynin is a classic STOPP-criterion drug.
  • Containment products manage symptoms but are not a diagnosis or a cure — always assess and treat the cause.
  • Do not catheterise or antibiotic-treat an older patient for 'incontinence' alone without urinary symptoms.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.